Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Clarivate PLC (CLVT) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.21 per share a year ago.

Clarivate PLC (CLVT) Q1 Earnings and Revenues Top Estimates

— Reaffirmed 2023 Outlook — LONDON , May 9, 2023 /PRNewswire/ -- Clarivate Plc - (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today reported results for the first quarter ended March 31, 2023. First  Quarter 2023 Financial Highlights Revenues of $629.1 million decreased 5.0%, and 3.1% at constant currency(1), driven primarily by the divestiture of MarkMonitor in October 2022, for which there were no comparable amounts in the current year period and year-over-year strengthening of the US dollar Organic revenues(1) decreased 0.2% as an increase in subscription revenues of 3.1% was partially offset by a decline in re-occurring revenues of 1.7% and transactional and other revenues of 8.3% Net income attributable to ordinary shares of $24.7 million decreased $26.1 million driven by the mark-to-market gain on financial instruments in the prior year quarter and an increase in interest costs, which was partially offset by a tax benefit in the current year quarter; Net income per diluted share of $0.04 increased by $0.10 Adjusted Net Income(1) of $130.9 million decreased 15.6%; Adjusted Income per diluted share(1) of $0.18 decreased 14.3% or $0.03 Adjusted EBITDA(1) of $252.7 million decreased 3.7% driven by the divestiture of MarkMonitor, partially offset by cost savings from integration programs; Adjusted EBITDA Margin(1) of 40.2% increased 60 basis points Net cash provided by operating activities increased $160.1 million to $227.5 million; Free cash flow(1) increased $142.2 million to $168.2 million, allowing for continued deleveraging through further debt reduction "Clarivate delivered results in line with our expectations for the first quarter including improved subscription revenue and strong cash flow," said Jonathan Gear, Chief Executive Officer.

Clarivate Reports First Quarter 2023 Results

Impactive's latest engagement with Clarivate shows how activists can seek potential in fallen SPAC stocks.

Impactive takes a stake in Clarivate and sets the tone for activism in the post-SPAC world

Report explores how developers are addressing challenges to market approvals and payment LONDON , May 2, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced the release of its new report, Making gene therapy work for patients, payers, regulators and developers: Five key trends in gene therapy approvals and access . The report explores the challenges and triumphs of gene therapy, with an eye on how developers are addressing risk and the need for multiple modalities and how payers are exploring alternative pay methods.

New Clarivate Report Identifies Trends in Gene Therapy Poised to Impact Patients, Payers, Regulators and Developers

Institute for Scientific Information prompts the U.S. to address shrinking domestic research capacity or risk its position as a leading science and technology power LONDON , April 27, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released an in-depth report from the Institute for Scientific Information (ISI)™ which examines the impact of globalization on United States research. The report emphasizes the importance of continued investment and collaboration to maintain the country's position as a leading science and technology power.

Clarivate Report on U.S. Research Emphasizes Need for Continued International Collaboration and Domestic Regional Investment

Concludes the appointments for business leaders of its three market segments LONDON , April 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today that it has appointed Henry Levy as President, Life Sciences & Healthcare, effective May 1, 2023. Henry joins from Veeva Systems, a global leader in cloud software for the life sciences industry, where he most recently served as President, Global R&D and Quality, with responsibility for driving sales across the segment.

Clarivate Appoints Henry Levy as President, Life Sciences & Healthcare

LONDON , April 20, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today it will report its financial results for the first quarter 2023 before the market opens on Tuesday, May 9. The press release and earnings supplement, with accompanying financial information, will be posted on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report First Quarter 2023 Results on May 9, 2023

Appointing the second of three business leaders for its newly created market segments LONDON , April 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Bar Veinstein will join the company as President, Academia & Government, effective April 24, 2023. Bar joins from Taranis, an AI-powered crop intelligence provider, where he was Chief Executive Officer focusing on driving business growth, improving customer satisfaction and accelerating the company's artificial intelligence (AI) strategy.

Clarivate Names Bar Veinstein as President, Academia & Government

Clarivate has plummeted over 70% from its all-time high. The business has been messy but the new management team is now cleaning things up and the fundamentals remain solid.

Clarivate: A Great Recovery Play

Clarivate has a strong business model with high barriers to entry, including high pricing power and excellent top-line visibility due to its recurring revenue model and high customer retention rates. CLVT has set new medium-term financial goals focused on accelerating organic revenue growth through investments in content and technology, with a target of growing organic revenue by around 6%.

Clarivate: Organic Growth To Drive EBITDA Expansion

The CLVT business is widely adopted in the industry and has proven to be enduring and difficult to replace. CLVT should be relatively recession-proof given its mission-critical solutions and the customer base.

Clarivate: Challenges To Deliver High Growth

Centessa Pharmaceuticals PLC

Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON , March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

LONDON , March 13, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today that Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the BofA Securities 2023 Information & Business Services Conference on Thursday, March 16, 2023 at 9:45 am Eastern Time. The live webcast can be accessed at https://bofa.veracast.com/webcasts/bofa/infoservices2023/idso9130.cfm and will be available for replay.

Clarivate to Present at the BofA Securities 2023 Information & Business Services Conference on March 16

Clarivate PLC (NYSE:CLVT ) Q4 2022 Earnings Conference Call March 1, 2023 9:00 AM ET Company Participants Mark Donohue - Head, IR Jonathan Gear - CEO & Director Jonathan Collins - EVP & CFO Conference Call Participants George Tong - Goldman Sachs Group Toni Kaplan - Morgan Stanley Seth Weber - Wells Fargo Securities John Mazzoni - RBC Capital Markets Stephanie Moore - Jefferies Adam Parrington - Stifel, Nicolaus & Company Peter Christiansen - Citigroup Operator Hello, and welcome to today's Clarivate Q4 and Full Year Earnings Conference Call. My name is Bailey, and I'll be the moderator for today's call.

Clarivate PLC (CLVT) Q4 2022 Earnings Call Transcript

Clarivate PLC (CLVT) delivered earnings and revenue surprises of 29.41% and 3.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Clarivate PLC (CLVT) Q4 Earnings and Revenues Top Estimates

— Provides 2023 Outlook — LONDON , March 1, 2023 /PRNewswire/ -- Clarivate Plc - (NYSE: CLVT) (the "Company" or "Clarivate"), a global leader in connecting people and organizations to intelligence they can trust, today reported results for the fourth quarter and full year ended December 31, 2022. Fourth  Quarter 2022 Financial Highlights Revenues of $675.3 million increased 20.4%, and 25.2% at constant currency(1), driven primarily by the acquisition of ProQuest Organic revenues(1) increased 0.5% as increases in subscription revenues of 2.5% and re-occurring revenues of 2.5% were partially offset by a decline in transactional and other revenues of 5.9% Net income attributable to ordinary shares was $304.3 million compared to Net loss attributable to ordinary shares of $130.4 million in the prior year quarter driven by the gain from the MarkMonitor divestiture; Net income per diluted share of $0.44 increased by $0.64 Adjusted Net Income(1) of $164.0 million increased 0.5%; Adjusted Income per diluted share(1) of $0.22 decreased 4.3% or $0.01 Adjusted EBITDA(1) of $304.4 million increased 18.6% driven by earnings contributions from acquisitions, organic growth and cost savings from integration programs; Adjusted EBITDA Margin(1) of 45.1% decreased 70 basis points Full Year 2022 Financial Highlights Revenues of $2,659.8 million increased 41.7%, and 46.9% at constant currency(1), driven primarily by the acquisition of ProQuest Organic revenues(1) increased 2.6% as increases in subscription revenues of 3.4% and re-occurring revenues of 5.2% were partially offset by a decline in transactional and other revenues of 2.7% Net loss attributable to ordinary shares of $4,035.6 million increased $3,723.6 million due to the $4,449.1 million non-cash impairment of goodwill; Net loss per diluted share of $6.24 increased by $5.63 Adjusted Net Income(1) of $628.0 million increased 30.4%; Adjusted Income per diluted share(1) of $0.85 increased 18.1% or $0.13 Adjusted EBITDA(1) of $1,112.7 million increased 39.0% and Adjusted EBITDA Margin(1) of 41.8% decreased 80 basis points Cash Flows from Operations increased $185.5 million to $509.3 million; Adjusted Free Cash Flow(1) increased $62.4 million to $521.8 million "2022 was a pivotal year for Clarivate as we made progress on many fronts and transitioned the company for future achievements," said Jonathan Gear, Chief Executive Officer.

Clarivate Reports Fourth Quarter and Full Year 2022 Results

—Clarivate will ring the opening bell at the New York Stock Exchange on March 6 — LONDON , Feb. 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today details for its upcoming Investor Day conference on Thursday, March 9, 2023 in New York. Due to limited capacity, in-person attendance is by invitation only.

Clarivate Announces Details of its Investor Day on March 9, 2023

Providing key insights for building a sustainable industry ecosystem LONDON , Feb. 22, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform the world, and the KAIST Innovation Strategy and Policy Institute (ISPI), a top research institution in South Korea today launched a collaborative report on the global innovation landscape of the artificial intelligence (AI) chip industry. The report suggests it is crucial to build an innovation ecosystem to stimulate mutual-cooperation among universities, enterprises and government-funded research institutes.

Clarivate and KAIST Innovation Strategy and Policy Institute Release Report on the Global AI Chip Innovation Landscape

New report identifies consistent above-the-bar innovation performance, and reveals top 50 most cited research organizations from the Top 100 by blending insights on inventive activity and scientific discovery LONDON , Feb. 16, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today revealed its 2023 list of Top 100 Global Innovators™ – companies and organizations which sit at the very top of the global innovation ecosystem, with the most consistent above-the-bar innovation performance. New this year: The report marries insights from Clarivate on inventive activity and scientific discovery to better track the flow of modern innovation - to identify the 50 research organizations most often cited by the Top 100 Global Innovators 2023.

Clarivate Names Top 100 Global Innovators 2023

Clarivate PLC (CLVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Clarivate PLC (CLVT) Upgraded to Strong Buy: Here's What You Should Know

Ares Capital

Deutsche Telekom AG

Haemonetics

 StoneX Group

SNEX, DTEGY, CLVT, HAE and ARCC have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.

New Strong Buy Stocks for February 10th

Helping researchers more easily access preprints within trusted platform to advance scientific progress LONDON , Feb. 9, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, has added the Preprint Citation Index™ to the Web of Science™ platform. Researchers can now locate and link to preprints alongside other trusted content in the database, to streamline the research process and help make meaningful connections faster.

Clarivate Adds Preprint Citation Index to the Web of Science

Here is how Clarivate PLC (CLVT) and Lyft (LYFT) have performed compared to their sector so far this year.

Is Clarivate (CLVT) Outperforming Other Computer and Technology Stocks This Year?

LONDON , Feb. 7, 2023 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today it will report its financial results for the fourth quarter and full year 2022 before the market opens on Wednesday, March 1. The press release and earnings supplement, with accompanying financial information, will be posted on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report Fourth Quarter and Full Year 2022 Results on March 1, 2023

In-depth analysis of obesity highlights latest advances in weight loss drugs, the search for biological fitness mediators and the pros and cons of weight as a proxy for health LONDON , Feb. 6, 2023 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, explores how difficult scientific detachment can be for health topics that have large cultural components- such as obesity. After many years of research and development, drug-induced weight loss has matured into a viable therapeutic option.

News for Clarivate Plc Stock (CLVT)